产品说明书

Rizatriptan benzoate

Print
Chemical Structure| 145202-66-0 同义名 : MK 462;Rizatriptan (benzoate salt);Maxalt;2-(5-((1H-1,2,4-TRIAZOL-1-YL)METHYL)-1H-INDOL-3-YL)-N,N-DIMETHYLETHANAMINE BENZOATE;MK-0462;MK-462 Benzoate
CAS号 : 145202-66-0
货号 : A343353
分子式 : C22H25N5O2
纯度 : 98%
分子量 : 391.466
MDL号 : MFCD00866224
存储条件:

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(127.72 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 100 mg/mL(255.45 mM),配合低频超声助溶

动物实验配方:
生物活性
描述 Rizatriptan Benzoate is an orally active serotonin 5-HT(1) receptor agonist that potently and selectively binds to 5-HT(1B/1D) subtypes. Oral rizatriptan 5 and 10mg have shown greater efficacy than placebo in providing pain relief, an absence of pain, relief from associated symptoms, normal functional ability and an improvement in patient quality of life. Rizatriptan 10mg provides faster pain relief and a higher percentage of patients with an absence of pain and normal functional ability at 2 hours than naratriptan 2.5mg or zolmitriptan 2.5mg[3]. Rizatriptan Benzoate is a selective 5-hydroxy tryptamine receptor agonist with anti migraine property. The rizatriptan benzoate oral disintegrating strip is potentially a useful tool for an effective treatment of migraine with improved bioavailability, rapid onset of action and with increased patient compliance[4]. Rizatriptan benzoate significantly reduced expression of the mRNAs for proenkephalin and substance P. Rizatriptan benzoate may inhibit the analgesic effect of the endogenous pain modulatory system[5]. In addition, the brain uptake potential of optimized RB-SLNs (rizatriptan benzoate-loaded solid lipid nanoparticles) to be 18.43-folds higher with respect to the pure drug in its free form, post 2 h of oral drug administration. RB-SLNs have distinctly improved brain target ability[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.55mL

0.51mL

0.26mL

12.77mL

2.55mL

1.28mL

25.54mL

5.11mL

2.55mL

参考文献

[1]Williamson DJ, Hill RG, et al. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol. 2001 Aug;133(7):1029-34.

[2]Williamson DJ, Shepheard SL, et al. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol. 1997 Jun 5;328(1):61-4.

[3]Wellington K, Plosker GL. Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539‐1574

[4]Bhagawati ST, Chonkar AD, Dengale SJ, Reddy SM, Bhat K. Bioavailability Enhancement of Rizatriptan Benzoate by Oral Disintegrating Strip: In vitro and In vivo Evaluation. Curr Drug Deliv. 2016;13(3):462‐470

[5]Yao G, Man Y, Luo X, Yu T, Ji L. Rizatriptan benzoate influences the endogenous pain modulatory system in a rat model of migraine. Neural Regen Res. 2012;7(2):131‐135

[6]Girotra P, Singh SK. Multivariate Optimization of Rizatriptan Benzoate-Loaded Solid Lipid Nanoparticles for Brain Targeting and Migraine Management. AAPS PharmSciTech. 2017;18(2):517‐528